Osiris Reports Interim Results For Phase-II Prochymal Trial

Osiris has reported six-month interim data from phase-II clinical trial, evaluating Prochymal for the treatment of chronic obstructive pulmonary disease (COPD).

In the placebo-controlled study, 62 patients were enrolled to be followed for two years. At the six-month time-point, the data revealed several important findings.

Findings suggested that Prochymal decreased systemic inflammation in patients as compared to those receiving placebo, as determined by C-reactive protein (CRP).

Despite the reduction in inflammation, pulmonary function in patients receiving Prochymal was not significantly improved, as compared to those receiving placebo.

Randal Mills, President and CEO, Osiris, said: We are very pleased with the interim outcome of this study and that the data continues to support the strong safety profile of this therapy, particularly given the severity of these patients’ pulmonary disease.

Importantly, we are gratified to obtain clear, objective data that helps bolster our understanding of the anti-inflammatory effects of these remarkable cells. Short-term, these anti-inflammatory effects did not appear to improve pulmonary function in patients with advanced destructive changes of the lung. Collectively however, these findings add to our confidence about the safety and effectiveness of the drug, he added.